UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma

British journal of haematology, 2012-11, Vol.159 (3), p.322-328

2012

Volltextzugriff (PDF)

Epidemiology and Environmental Aspects of Marginal Zone Lymphomas

Best practice & research. Clinical haematology, 2017-03, Vol.30 (1-2), p.84-91

2017

Volltextzugriff (PDF)

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

British journal of haematology, 2011-05, Vol.153 (4), p.451-485

2011

Volltextzugriff (PDF)

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Journal of clinical oncology, 2014-04, Vol.32 (12), p.1236-1241

2014

Volltextzugriff (PDF)

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Blood, 2011-11, Vol.118 (22), p.5799-5802

2011

Volltextzugriff (PDF)

Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

British journal of haematology, 2009-06, Vol.145 (6), p.733-740

2009

Volltextzugriff (PDF)

Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2010-04, Vol.16 (2), p.150-151

2010

Volltextzugriff (PDF)

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

The New England journal of medicine, 2002-08, Vol.347 (7), p.481-487

2002

Volltextzugriff (PDF)

Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

British journal of haematology, 2010-06, Vol.149 (6), p.907-910

2010

Volltextzugriff (PDF)

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Blood, 2001-09, Vol.98 (6), p.1721-1726

2001

Volltextzugriff (PDF)

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

Leukemia & lymphoma, 2011-06, Vol.52 (S2), p.75-78

2011

Volltextzugriff (PDF)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

Cancer, 2011-06, Vol.117 (11), p.2452-2460

2011

Volltextzugriff (PDF)

High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD

Clinical transplantation, 2013-01, Vol.27 (1), p.E56-E63

2013

Volltextzugriff (PDF)

T-cell prolymphocytic leukemia

Medical oncology (Northwood, London, England), 2006, Vol.23 (1), p.17-22

Dearden, Claire E

2006

Volltextzugriff (PDF)

T-Cell Prolymphocytic Leukemia

Clinical lymphoma & myeloma, 2009-09, Vol.9, p.S239-S243

Dearden, Claire E.

2009

Volltextzugriff (PDF)

Epstein‐Barr virus negative large B‐cell lymphoma during long term immunomodulatory therapy for T‐cell large granular lymphocytic leukaemia

British journal of haematology, 2010-01, Vol.148 (2), p.337-339

2010

Volltextzugriff (PDF)

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

British journal of haematology, 2005-06, Vol.129 (5), p.607-614

2005

Volltextzugriff (PDF)

Alemtuzumab in T-cell malignancies

Medical oncology (Northwood, London, England), 2002-01, Vol.19 Suppl (2S), p.S27-S32

2002

Volltextzugriff (PDF)

Membrane phenotype and response to deoxycoformycin in mature T cell malignancies

BMJ, 1987-10, Vol.295 (6603), p.873-875

1987

Volltextzugriff (PDF)

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

The New England journal of medicine, 2014-07, Vol.371 (3), p.213-223

2014

Volltextzugriff (PDF)

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Clinical cancer research, 2015-09, Vol.21 (18), p.4174-4183

2015

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

Humans
(32)
Life Sciences & Biomedicine
(30)
Middle Aged
(30)
Science & Technology
(30)
Male
(29)
Female
(25)
Adult
(24)
Hematology
(17)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Treatment Outcome
(15)
Aged, 80 And Over
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Hematologic And Hematopoietic Diseases
(13)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Alemtuzumab
(9)
Oncology
(9)
Prognosis
(9)
Antineoplastic Agents - Therapeutic Use
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma

Epidemiology and Environmental Aspects of Marginal Zone Lymphomas

Guidelines for the management of mature T‐cell and NK‐cell neoplasms (excluding cutaneous T‐cell lymphoma)

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis

Ocular and cerebral aspergillosis in a non-neutropenic patient following alemtuzumab and methyl prednisolone treatment for chronic lymphocytic leukaemia

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta

Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD

T-cell prolymphocytic leukemia

T-Cell Prolymphocytic Leukemia

Improved relapse‐free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation‐Intergroup study

Epstein‐Barr virus negative large B‐cell lymphoma during long term immunomodulatory therapy for T‐cell large granular lymphocytic leukaemia

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

Alemtuzumab in T-cell malignancies

Membrane phenotype and response to deoxycoformycin in mature T cell malignancies

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing

Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia

Aktive Filter

Suchergebnisse filtern